Compared with the trial results of EUCLID and PEGASUS, the COMPASS trial advances the field of cardiovascular disease in combination therapies, said John Eikelboom, MD, of McMaster University.
Compared with the trial results of EUCLID and PEGASUS, the COMPASS trial advances the field of cardiovascular disease in combination therapies, said John Eikelboom, MD, of McMaster University.
Transcript (slightly modified)
Can you put the results of the COMPASS trial in perspective compared with the results of the EUCLID and PEGASUS trials?
The recent trials EUCLID and PEGASUS attempted to improve on the existing standard of care by evaluating alternative, more intensive, antithrombotic strategies. If we take EUCLID, this was a trial in patients with peripheral artery disease that evaluated ticagrelor as an alternative to clopidogrel. The EUCLID trial was very important, very large, a well-done study and it showed absolutely no benefit of ticagrelor. Thus, the EUCLID trial didn’t really advance treatment in peripheral artery disease.
The PEGASUS trial was an important, and, again, global, large, well-done study in patients post-myocardial infarction. In this trial, 2 doses of ticagrelor that were tested were on top of aspirin and the results indicate a reduction in major adverse cardiovascular events, an increase in bleeding, and no overall mortality benefit. So, in this context, the results of COMPASS really advanced the field because the combination therapy in COMPASS doesn’t only reduce major adverse cardiovascular events, but also reduces total mortality.
Children With AD, Neurodevelopmental Comorbidities at Greater Odds of Learning, Memory Difficulties
March 18th 2024Children with atopic dermatitis (AD) face higher chances of learning and memory difficulties, particularly when they have neurodevelopmental comorbidities, like attention-deficit/hyperactivity disorder.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Disease-, Age-, Genomic-Specific Factors Increase Risk of ET, PV, PrePMF Developing Into Overt MF
March 16th 2024New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).
Read More